Claims:

~~1. An antibody which has the ability of binding to GT468 and has one or more of the following activities:~~

~~(i) killing of tumor cells expressing GT468,~~

~~(ii) inhibition of proliferation of tumor cells expressing GT468,~~

~~(iii) inhibition of colony formation of tumor cells expressing GT468, and~~

~~(iv) inhibition of metastasis of tumor cells expressing GT468.~~

~~2. The antibody of claim 1 wherein said one or more activities are induced by binding of said antibody to the extracellular domain of GT468 expressed by said cells.~~

~~3. The antibody of claim 1 or 2 wherein said tumor cells expressing GT468 are cancer cells.~~

~~4. The antibody of claim 3 wherein the cancer cells are from a cancer selected from the group consisting of breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof, and metastatic cancer in the lung..~~

~~5. The antibody of any one of claims 1-4 which is a monoclonal, chimeric, human or humanized antibody, or a fragment of an antibody.~~

~~6. The antibody of any one of claims 1-5 wherein GT468 has the amino acid sequence according to SEQ ID NO: 2.~~

~~7. The antibody of any one of claims 1-6 wherein the antibody binds specifically to GT468.~~

~~8. The antibody of any one of claims 1-7 which binds to native epitopes of GT468.~~

~~9. The antibody of any one of claims 1-8 which is obtainable by a method comprising the step of immunizing an animal with a protein or peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2-10 and 35-82, or an immunogenic fragment or derivative thereof, or a nucleic acid or host cell expressing said protein or peptide, or immunogenic fragment or derivative thereof.~~

~~10~~1. An antibody selected from the group consisting of:

(i) an antibody produced by or obtainable from a clone deposited under the accession no. ~~DSM ACC2822 (4E9 1H9), DSM ACC2826 (9B6 2A9), DSM ACC2824 (59D6 2F2), DSM ACC2825 (61C11 2B5), DSM ACC2823 (78H11 1H6),~~ DSM ACC2895 (22-1A-1), DSM ACC2893 (22-2A-1), DSM ACC2896 (22-9B-1), DSM ACC2897 (23-33A-1), DSM ACC2891 (23-19A-1), DSM ACC2894 (F11#33F7D12), DSM ACC2892 (4A12 2D4 1A10), DSM ACC2898 (4E9 1D12 2D4), DSM ACC2961 (42H11 1C11 2B2), DSM ACC2962 (51G6 2H3 2B4), DSM ACC2943 (16-5B-1), DSM ACC2956 (20-11A-1), DSM ACC2947 (29-1A-2), DSM ACC2964 (29-8B-1), DSM ACC2959 (35-48B-1), DSM ACC2963 (35-50A-2a), DSM ACC2957 (38-10B-1), DSM ACC2958 (38-1A-1), DSM ACC2948 (44-3A-2), DSM ACC2949 (45-2A-1), DSM ACC2950 (45-8A-2), DSM ACC2951 (48-3B-1), DSM ACC2952 (48-4A-1), DSM ACC2946 (49-3A-1), DSM ACC2945 (49-8A-1), DSM ACC2944 (51-1A-1), DSM ACC2953 (53-13A-2), DSM ACC2955 (53-29A-1), DSM ACC2960 (54-4B-2), DSM ACC2954 (56-4A-2), or DSM ACC3001 (62-9B-1),

(ii) an antibody which is a chimerized or humanized form of the antibody under (i),

(iii) an antibody which has the specificity of the antibody under (i), and

(iv) an antibody comprising the antigen binding portion or antigen binding site of the antibody under (i).

~~11~~2. The antibody of claim ~~10~~1, wherein the antigen binding portion or antigen binding site of the antibody under (i) comprises the variable region of the antibody under (i).

~~12~~3. A hybridoma capable of producing the antibody of ~~any one of~~ claims 1 ~~to~~or ~~11~~2.

~~13~~4. A hybridoma deposited under the accession no. ~~DSM ACC2822 (4E9 1H9), DSM ACC2826 (9B6 2A9), DSM ACC2824 (59D6 2F2), DSM ACC2825 (61C11 2B5), DSM ACC2823 (78H11 1H6),~~ DSM ACC2895 (22-1A-1), DSM ACC2893 (22-2A-1), DSM

ACC2896 (22-9B-1), DSM ACC2897 (23-33A-1), DSM ACC2891 (23-19A-1), DSM ACC2894 (F11#33F7D12), DSM ACC2892 (4A12 2D4 1A10), DSM ACC2898 (4E9 1D12 2D4), DSM ACC2961 (42H11 1C11 2B2), DSM ACC2962 (51G6 2H3 2B4), DSM ACC2943 (16-5B-1), DSM ACC2956 (20-11A-1), DSM ACC2947 (29-1A-2), DSM ACC2964 (29-8B-1), DSM ACC2959 (35-48B-1), DSM ACC2963 (35-50A-2a), DSM ACC2957 (38-10B-1), DSM ACC2958 (38-1A-1), DSM ACC2948 (44-3A-2), DSM ACC2949 (45-2A-1), DSM ACC2950 (45-8A-2), DSM ACC2951 (48-3B-1), DSM ACC2952 (48-4A-1), DSM ACC2946 (49-3A-1), DSM ACC2945 (49-8A-1), DSM ACC2944 (51-1A-1), DSM ACC2953 (53-13A-2), DSM ACC2955 (53-29A-1), DSM ACC2960 (54-4B-2), DSM ACC2954 (56-4A-2), or DSM ACC3001 (62-9B-1),.

~~14~~5. A conjugate comprising an antibody of ~~any one of~~ claims ~~1 to~~or ~~11~~ 2 coupled to a therapeutic agent.

~~15~~6. The conjugate of claim ~~14~~ 5 wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent.

~~16~~7. A pharmaceutical composition comprising an antibody of ~~any one of~~ claims ~~1 to~~or ~~11~~ 2 and/or a conjugate of claim ~~14~~ 5 or ~~15~~6, and a pharmaceutically acceptable carrier.

~~17~~8. Use of the antibody of claim 1 or 2 and/or the conjugate of claim 5 or 6 in the manufacture of a pharmaceutical composition for use in a~~A~~ method of inhibiting growth of a cell expressing GT468 and/or being characterized by association of GT468 with its cell surface~~, comprising contacting the cell with an antibody of any one of claims 1 to 11 and/or a conjugate of claim 14 or 15~~.

~~18~~9. Use of the antibody of claim 1 or 2 and/or the conjugate of claim 5 or 6 in the manufacture of a pharmaceutical composition for use in a~~A~~ method of killing a cell expressing GT468 and/or being characterized by association of GT468 with its cell surface~~, comprising contacting the cell with an effective amount of an antibody of any one of claims 1 to 11 and/or a conjugate of claim 14 or 15~~.

~~19~~10. Use of the antibody of claim 1 or 2 and/or the conjugate of claim 5 or 6 in the manufacture of a pharmaceutical composition for use in a~~A~~ method of inhibiting metastatic spread of a cell expressing GT468 and/or being characterized by association of GT468 with its cell surface~~, comprising contacting the cell with an effective amount of an antibody of any one of claims 1 to 11 and/or a conjugate of claim 14 or 15~~.

~~20~~11. Use of the antibody of claim 1 or 2 and/or the conjugate of claim 5 or 6 in the manufacture of a pharmaceutical composition for use in a~~A~~ method of treating or preventing a disease or disorder involving cells expressing GT468 and/or being characterized by association of GT468 with their cell surface in a subject~~, comprising administering to said subject an antibody of any one of claims 1 to 11, a conjugate of claim 14 or 15 or a pharmaceutical composition of claim 16~~.

~~21~~12. The ~~method~~ use of claim ~~20~~ 11 wherein the disease or disorder is a tumor-related disease.

~~22~~13. The ~~method~~ use of claim ~~21~~ 12 wherein the tumor-related disease is cancer.

~~23~~14. The ~~method~~ use of claim ~~22~~ 13 wherein the cancer is selected from the group consisting of breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof, and metastatic cancer in the lung.